Introduction {#S1}
============

Aging of population is rapidly accelerating, with dramatic increase of people older than 65 years and a change in the age structure of worldwide population ([@B11]). Aging is a physiologic process characterized by a gradual impairment in many body functions and growing risk of disease ([@B20]), with a decrease in strength, flexibility, aerobic capacity, and force output due to progressive loss of muscle tissue and free fat mass whereas fat mass tend to increase ([@B57]).

Evidence from human studies supports the notion that regular, vigorous aerobic exercise is a useful tool, with a dose-response effect, to improve the overall health status and longevity ([@B53]; [@B48]). Exercise stimulates the release of cytokines with autocrine, paracrine and endocrine functions produced in skeletal muscle, termed myokines. Thus, skeletal muscle can be classified as endocrine organ. Irisin and myostatin are myokines involved in adaptations to regular training such as increased muscle mass or muscle hypertrophy. Irisin seems a positive regulator whereas myostatin inhibits muscle growth ([@B25]).

Irisin is the result of proteolytic cleavage product of the fibronectin type III "domain-containing" protein 5 (FDNC5) and acts on skeletal muscle, resulting in increased energy expenditure and oxidative metabolism through the induction of metabolic genes ([@B34]). Previous reports demonstrated anti-diabetic effect of irisin through increased energy expenditure in mice ([@B5]). Moreover, irisin plays a key role on the skeleton by increasing cortical bone mineral density, modifying its structure and improving bone strength ([@B13]). In humans, contradictory effects of exercise in irisin levels have been reported ([@B42]; [@B38]; [@B49]). While higher irisin plasma levels after exercise in humans have been described, [@B54] using gene expression arrays, failed to detect a robust and consistent increase in FNDC5 mRNA in human muscle biopsies after exercise. The threshold of exercise required to produce these effects might be crucial, because acute exercise has been demonstrated to result in increased serum irisin concentrations in humans ([@B22]; [@B3]). Lower circulating irisin is a marker of muscle weakness and atrophy and is associated with total muscle mass ([@B22]; [@B26]; [@B10]). Taken together, these data suggest that resistance exercise may result in increased circulating irisin.

Myostatin, also known as growth differentiation factor 8, is a secreted TGF-β superfamily protein that is expressed in skeletal muscle, controlling myoblast proliferation, but being a potent negative regulator of skeletal muscle growth and development ([@B31]). Myostatin is synthesized as a 376 amino acid (aa) preprotein that consists of 24 aa signal peptide, a 243 aa propeptide, and a 109 aa mature protein ([@B40]). The secreted proprotein is cleaved by BMP-1 family proteases to separate the propeptide from the bioactive mature protein ([@B32]; [@B68]; [@B62]). This cleavage results in a latent complex containing a disulfide-linked dimer of the mature protein and two associated propeptides ([@B32]; [@B68]), in which the myostatin propeptide inhibits the active form.

In the current study, we aimed to investigate the association between resistance exercise and circulating levels of irisin and myostatin in elderly subjects (more than 60 years).

Materials and Methods {#S2}
=====================

Subjects' Recruitment {#S2.SS1}
---------------------

This is a prospective and controlled clinical trial in which subjects were randomized into 3 groups: (1) control group (*n* = 15), (2) resistance exercise group (RE) (*n* = 14), and (3) resistance exercise nutritional support group (RENS) (*n* = 9) during 16 weeks. To increase the sample size of control group, five additional patients were recruited. Randomization was done with the EPIDAT 4.0 program. The subjects (men and women aged 60--75 years) residing in province of Girona, Spain; users of civic centers and primary health care center were invited to participate. Those who accepted were enrolled after giving written informed consent, being studied at baseline and after 16 weeks. This study excluded subjects who (i) were known to have associated chronic diseases (i.e., type 2 diabetes poorly controlled); (ii) were under treatment that could cause myopathy; and (iii) suffer from dementia, cognitive limitation, respiratory impairment or malnutrition (IMC \<17 kg/m2, involuntary weight loss \>10% and albumin levels \<2.5 g/dl).

The night before the visit, all participants followed their usual diet. The post-intervention visit was performed a week after the last session of exercise. For each patient the following measurements at baseline and at post-intervention visit were carried out: (i) Analysis of the biochemical parameters at fasting state; (ii) Anthropometric measurements: brachial circumference, arm circumference, calf circumference, abdominal circumference, tricipital fold; (iii) Fragility test ([@B17]); (iv) World Health Organization Quality of Life -- BREF (WHOQOL-BREF); (v) Mini nutrition assessment (MNA); (vi) Evaluation of muscle strength with a dynamometer; (vii) Assessment of the physical condition with the Short Physical Performance Battery (SPPB).

Exercise Program {#S2.SS2}
----------------

The exercise program lasted 16 weeks and followed the basic principles of the training: (1) loading principle, (2) progression, (3) specificity and individuality, and (4) recovery \[American college of sport medicine position stand (1998)\]. The subjects performed two weekly sessions of approximately 45 min, with a minimum day of rest between sessions. The session consisted of 3 parts: (i) Warm up with stretching and joint mobilization exercise; (ii) Main part where the resistance exercises will be worked out: 4 upper body exercises and 3 lower body exercises; (iii) Return to the calm with stretching and relaxation. The first weeks of the program were for the anatomical adaptation and the knowledge for the exercises execution; later and progressively increased the load and the volume. All subjects were directly supervised by the physical educator who was in charge.

Nutritional Intervention {#S2.SS3}
------------------------

The individuals in the control group (C) and the resistance exercise group (RE) followed their usual diet. Individuals in the resistance exercise and nutritional support group (RENS) followed a balanced and varied diet. A protein intake of 0.8--1 g of protein per kg of weight was guaranteed, distributed in 3 meals per day (breakfast/lunch/dinner). The protein intake was calculated from three 24-h reminders as previously reported ([@B63]). Dietary advice was given to follow a diet enriched with proteins and also was provided with powdered protein (calcium caseinate, T. Aliment -- Espècies Teixidor, Barcelona, Spain).

### Nutritional Support {#S2.SS3.SSS1}

The 10 g of protein (calcium caseinate) powder diluted in water or juice was taken daily at breakfast and twice week additional 10 g of protein administration just after exercise performance.

Analytical Methods {#S2.SS5}
------------------

Serum glucose, glycated hemoglobin (HbA1c), serum insulin, total cholesterol, LDL and HDL cholesterol, triglycerides, were determined as described elsewhere ([@B42]). C-reactive protein (ultrasensitive assay; 110 Beckman, Fullerton, CA, United States) was determined by a routine laboratory test. Leucocytes, neutrophils and lymphocytes cell count and albumin and creatinine measurement was performed by routine laboratory analysis. Irisin were determined using Irisin ELISA Kit (Catalog Number RAG018R, BIOVENDOR, Brno, Czechia). According to manufacturer information, this ELISA is specific for the measurement of natural and recombinant irisin in human samples, and it does not cross-react with FNDC4, human adiponectin, human Nampt, human RBP4, human clusterin, human leptin, human vaspin, human GPX3, human resistin, human ACE2, human lipocalin-2, human ANGPTL3, human ANGPTL6, human DNER, human DLK1, human calreticulin, and human IL-33. Myostatin concentrations were measured by Quantikine^®^ELISA GDF-8 / Myostatin Immunoassay (Catalog Number DGDF80, R&D Systems, Inc., Minneapolis, MN, United States). In both irisin and myostatin ELISA, intra- and interassay coefficients of variation were lower than 10%. Irisin was analyzed in all participants from RE and RENS group, but only in first recruited control (*n* = 15) subjects. Otherwise myostatin, which was measured several months after the end of the study, was analyzed in all participants.

Statistical Analyses {#S2.SS6}
--------------------

Statistical analyses were performed using SPSS 12.0 software. Unless otherwise stated, descriptive results of continuous variables are expressed as mean and SD for Gaussian variables or median and interquartile range. The relation between variables was analyzed by simple correlation (Spearman's test). One factor ANOVA with *post hoc* Bonferroni test and paired *t*-test were used to compare categorical parameters. Levels of statistical significance were set at *p* \< 0.05.

Results {#S3}
=======

The current study included 20 participants (18 women and 2 men) in C, 14 participants (12 women and 2 men) in RE and 9 participants (only women) in RENS, with an age range of 60--75 years-old ([Table 1](#T1){ref-type="table"}). Mean age was significantly higher in RENS compared to RE group (71.2 ± 3.3 vs. 64.9 ± 5.5, *p* = 0.02) ([Table 1](#T1){ref-type="table"}).

###### 

Evolution of body composition, anthropometric parameters walking speed and strength.

                                  **Control (*n* = 20)**   **RE (*n* = 14)**   **RENS (*n* = 9)**                                                                                                  
  ------------------------------- ------------------------ ------------------- -------------------- -------------- -------------- ----------- ----------------- -------------- ----------- ------- -----------
  Age                             66.4 (±4.6)              64.9 (±5.5)         71.2 (±3.3)^\#∇^     **0.016**                                                                                      
  Weight (kg)                     71 (±14.3)               70.7 (±14.7)        0.530                68.9 (±14.2)   68.7 (±14.1)   0.444       72.3 (±11.6)      72.5 (±12)     0.465       0.813   0.800
  BMI (kg/m^2^)                   28.9 (±4.6)              28.7 (±4.8)         0.231                29.1 (±4.8)    29 (±4.7)      0.505       30 (±2.8)         30.1 (±3.1)    0.525       0.861   0.723
  Waist perimeter (cm)            93 (±11.9)               90 (±10.7)          **0.003**            92.8 (±14.4)   92.6 (±14.2)   0.837       96.1 (±9.9^\*^)   96.1 (±10.5)   0.809       0.727   0.670
  Arm circumference (cm)          31.6 (±4)                31.8 (±4.2)         0.589                31 (±2.3)      31.4 (±3)      0.243       32.2 (±3.3)       32.4 (±3)      0.635       0.675   0.806
  Muscle arm circumference (cm)   23.6 (±2.7)              24 (±2.1)           0.443                22.5 (±2)      23.3 (±2.6)    0.088       23.3 (±3)         24.3 (±2)      **0.038**   0.451   0.621
  Abdominal circumference (cm)    105 (±11)                105 (±10)           0.664                92 (±10)       84 (±9)        0.287       97.5 (±12.9)      102 (±7.9)     0.231       0.160   **0.040**
  Calf circumference (cm)         33.1 (±3)                32 (±2.8)           **0.008**            33 (±2.4)      32.7 (±2.1)    0.504       32.3 (±4.3)       36.4 (±1.3)    **0.025**   0.735   **0.001**
  Basal metabolism (kcal)         1372 (±218)              1347 (222)          **0.004**            1307 (±254)    1306 (±259)    0.824       1390 (±208)       1409 (±208)    **0.038**   0.600   0.554
  Fat mass (kg)                   25.1 (±8.6)              25.9 (±8.8)         **0.043**            24.8 (±8.5)    24.6 (±7.7)    0.763       25.7 (±6.5)       25.1 (±7.1)    0.294       1       0.911
  \% Fat mass                     34.9 (±5.2)              36.1 (±5.6)         **0.005**            36.3 (±6.6)    36.1 (±5.8)    0.665       35.2 (±6)         34.1 (±6.7)    0.111       0.859   0.560
  Fat free mass (kg)              46 (±7.5)                45 (±7.7)           **0.002**            43.8 (±9.5)    43.7 (±9.9)    0.733       46.5 (±7.4)       47.4 (±7.4)    **0.046**   0.511   0.583
  \% Fat free mass                65.4 (±5.6)              64 (±5.2)           **0.003**            63.1 (±6.6)    63.1 (±5.9)    0.909       65 (±6)           65.7 (±6.7)    0.377       0.692   0.5534
  Total water (%)                 45.4 (±3.4)              44.7 (±3.4)         0.051                45.3 (±4.6)    45.2 (±4)      0.6781      45.1 (±3.9)       456 (±4.5)     0.102       0.739   0.699
  Total water (kg)                31.8 (±4.9)              31.1 (±4.9)         **0.016**            30.5 (±6.6)    30.4 (±4)      0.696       32.5 (±5)         32 (±7.9)      0.457       0.369   0.906
  Speed at 2.44 m                 3.2 (±0.75)              3 (±0.73)           0.082                3.5 (±0.7)     2.9 (±0.5)     **0.005**   3.5 (±0.7)        3.5 (±0.8)     0.881       0.589   0.107
  Speed at 4.5 m                  5.6 (±1.2)               5.2 (±0.9)          0.134                5.9 (±0.9)     5.2 (±0.1)     **0.013**   5.9 (±1)          5.9 (±1.1)     0.961       0.460   0.140
  Speed at 3 m                    3.7 (±0.7)               3.4 (±0.7)          **0.016**            3.89 (±0.7)    3.2 (±0.6)     **0.003**   3.9 (0.9)         3.8 (±1)       0.791       0.773   0.210
  Grip strength (kg)              16.7 (±4.9)              17 (±5.6)           0.639                15.3 (±4.6)    17.2 (±4.6)    **0.011**   16.8 (±5.9)       17.8 (±6.5)    0.185       0.638   0.946

\*

p

-value applying T student for matched data.

∗∗

p

-value applying one-way anova.

\#

p

= 0.03 compared to C.

∇

p

= 0.02 compared to RE. Bolded values mean statistical significance (

p

\< 0.05).

Changes in body composition, anthropometric and physical condition parameters at baseline and at the end of study in each group were shown in [Table 1](#T1){ref-type="table"}. At baseline, no significant differences were found between control and intervention groups ([Table 1](#T1){ref-type="table"}).

Compared to C, RENS resulted in increased percent change of fat free mass kg and calf circumference and in decreased percent change of fat mass kg ([Figure 1A](#F1){ref-type="fig"}). RE also resulted in increased percent change of fat free mass kg compared to C (*p* = 0.027) ([Figure 1A](#F1){ref-type="fig"}).

![**(A)** Comparison of percent change of fat free mass, calf circumference and fat mass according to control (C), resistance exercise (RE), and resistance exercise plus nutritional support (RENS). **(B)** Comparison of circulating irisin according to arm strength in C, RE, and RENS groups.](fphys-10-00871-g001){#F1}

In C group, a significant decrease in waist and calf circumference, fat free mass, HbA1c, serum myostatin and speed at 3 m, but in the context of increased fat mass was found ([Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}). In RE group, a significant increase in strength and circulating irisin, and a decrease in speed at 2.44, 4.5, and 3 m was found ([Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}). In RENS group, a significant increase in muscle arm circumference, calf circumference, fat free mass and circulating irisin was observed ([Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}). Interestingly, in this group, strength was positively correlated with fat free mass \[(*r* = 0.782, *p* = 0.008), [Table 3](#T3){ref-type="table"}\].

###### 

Clinical and biochemical parameters in study cohort.

                               **Control (*n* = 20)**   **RE (*n* = 14)**   **RENS (*n* = 9)**                                                                                                        
  ---------------------------- ------------------------ ------------------- -------------------- ----------------- -------------- ----------- -------------- ---------------- ----------- ----------- -----------
  Glucose (mg/dl)              110 (±33)                109 (±19)           0.878                104 (±26)         102 (±22)      0.613       97 (±10)       98 (±8)          0.557       0.473       0.279
  Insulin (μIU/ml)             7.2±15)                  7.1 (±4)            0.954                14.1 (±23)        7.6 (±4.8)     0.295       4.4 (±8.7)     8.4 (±5.8)       0.075       0.316       0.793
  HbA1c (%)                    5.8 (±0.5)               5.7 (±0.5)          **0.008**            5.8 (±0.8)        6 (±0.5)       0.088       5.5 (±0.3)     5.6 (±0.3)       0.399       0.3475      0.634
  HOMA                         2.8 (±2.5)               2 (±1.4)            0.243                5.3 (±10.7)       2 (±1.6)       0.297       1 (±2.3)       2.1 (±1.6)       0.076       0.297       0.966
  Albumin (g/dl)               4.5 (±0.2)               4.4 (±0.2)          **0.043**            4.5 (±0.2)        4.4 (±0.2)     0.497       4.3 (±0.1)     4.2 (±0.1)       0.282       0.052       0.128
  Protein (g/dl)               7.1 (±0.3)               7.1 (±0.3)          0.523                7.1 (±0.3)        7 (±0.3)       0.088       6.9 (±0.1)     6.9 (±0.1)       0.255       0.354       0.302
  Total cholesterol (mg/dl)    210 (±30)                203 (±30)           0.073                224 (±56)         227 (±68)      0.728       214 (±37)      217 (±42)        0.0624      0.619       0.336
  HDL-cholesterol (mg/dl)      65 (±14)                 61 (±14)            0.110                61 (14)           62 (±15)       0.805       64 (±16)       63 (±15)         0.566       0.758       0.972
  LDL-cholesterol (mg/dl)      125 (±28)                120 (±128)          0.192                141 (±52)         144 (±60)      0.755       130 (±36)      134 (±41)        0.622       0.467       0.266
  Triglycerides (mg/dl)        101 (±36)                105 (±38)           0.570                117 (±76)         122 (±94)      0.453       96 (±41)       100 (±47)        0.544       0.592       0.623
  C-reactive protein (mg/dl)   2.2 (8.3)                1.5 (±3)            0.642                0.7 (±1.3)        0.8 (±2.4)     0.858       0.3 (±0.2)     0.4 (±0.3)       0.326       0.614       0.533
  Leucocytes                   6.8 (±2.3)               6.1 (±1.4)          0.128                5.7 (±1.7)        6 (±2)         0.141       5.6 (±0.9)     5.7 (±1)         0.471       0.120       0.821
  Neutrophils                  3825 (±1910)             3310 (±1042)        0.134                3100 (±1204)      3240 (±1382)   0.348       3211 (±726)    3211 (±765)      0.405       0.289       0.973
  Lymphocytes                  2059 (±608)              2047 (±587)         0.482                2000 (±633)       1866 (±588)    0.191       1940 (±765)    1760 (±613)      0.301       0.449       0.709
  Irisin (μg/ml)^\#^           3.1 (±0.9)               3.5 (±1.1)          0.127                2.4 (±0.3)        3.1 (±0.8)     **0.011**   2.6 (±1.3)     3 (±1.1)         **0.030**   0.116       0.407
  Myostatin (ng/dl)            2.5 (1.8--3.1)           1.9 (1.5--2.3)      **0.003**            1.37 (1.2--2.2)   2 (1.4--2.5)   0.203       2.3 (2--2.9)   2.1 (1.8--3.4)   0.736       **0.025**   **0.048**

\*

p

-value applying T student for matched data.

∗∗

p

-value applying one-way anova.

\#

In control group was analyzed only in 15 participants (as explained in methods), whereas in RE and RENS was analyzed in all participants. Bolded values mean statistical significance (

p

\< 0.05).

###### 

Bivariate correlations between strength with anthropometric parameters.

                                    **Strength (at follow-up)**                                   
  --------------------------------- ----------------------------- ------- ------- ------- ------- -----------
  Fat free mass at follow-up (kg)   0.232                         0.311   0.413   0.183   0.782   **0.008**
  Muscle mass at follow-up (kg)     0.232                         0.311   0.413   0.183   0.782   **0.008**
  Protein mass at follow-up (kg)    0.122                         0.608   0.521   0.101   0.770   **0.009**
  Bone at follow-up (kg)            0.141                         0.532   0.393   0.165   0.782   **0.008**

Bold values mean statistical significance (

p

\< 0.05).

Since mean age in RENS was higher than in RE, multivariate regression analysis was performed after adjusting for age. This analysis indicated that fat-free mass (β = 0.850, *p* = 0.004) contributed independently to strength variance at follow up after controlling for age in RENS group.

The study showed a percentage of change in force of 2.9% in C group, of 16% in RE and 4% in RENS (*p* = 0.181). In RE group, the gain of strength expressed in kg significantly increased from an at baseline strength (from 15.3 to 17.2 kg, *p* = 0.011), and in RENS group also tended to increase (from 16.8 to 17.8 kg, *p* = 0.185). Moreover, in RENS group, the force was positively correlated with kg of fat-free mass (*p* = 0.008), kg of muscle mass (*p* = 0.008), kg of bone (*p* = 0.008) and kg protein mass (*p* = 0.009) ([Tables 1](#T1){ref-type="table"}, [3](#T3){ref-type="table"}).

Of note, in RENS group, circulating irisin was significantly decreased in those participants with decreased arm strength at the end of the study ([Figure 1B](#F1){ref-type="fig"}).

No significant correlation between circulating irisin and myostatin in any group was observed ([Table 4](#T4){ref-type="table"}).

###### 

Bivariate correlations between Irisin and Myostatin.

  **Control (*n* = 15)**                                                                                  
  ------------------------------- --------- ----------- --------- ------- --------- ----------- --------- -----------
  Irisin (at baseline) (μg/ml)    --        --          --0.027   0.928   0.470     0.077       0.333     0.266
  Irisin (at follow-up) (μg/ml)   0.470     0.077       0.099     0.748   --        --          --0.041   0.894
  RE (*n* = 14)                                                                                           
  Irisin (at baseline) (μg/ml)    --        --          0.057     0.846   --0.013   0.965       --0.537   **0.048**
  Irisin (at follow-up) (μg/ml)   --0.013   0.965       0.011     0.970   --        --          0.132     0.653
  RENS (*n* = 9)                                                                                          
  Irisin (at baseline) (μg/ml)    --        --          --0.683   0.042   0.833     **0.005**   --0.483   0.187
  Irisin (at follow-up) (μg/ml)   0.833     **0.005**   --0.467   0.205   --        --          --0.483   0.187

Bold values mean statistical significance (

p

\< 0.05).

At baseline, no significant correlation between circulating irisin and anthropometrical and clinical parameters were observed. Circulating myostatin was positively correlated with weight, muscle arm circumference, basal metabolism, fat-free mass, total water and negatively correlated with C-reactive protein ([Table 5](#T5){ref-type="table"}). In control group, circulating myostatin was positively correlated with speed at 2.44 m ([Figure 2](#F2){ref-type="fig"}).

###### 

Bivariate correlations between anthropometrical and clinical parameters and circulating irisin and myostatin in all participants at baseline.

                                  **Irisin**   **Myostatin**             
  ------------------------------- ------------ --------------- --------- -----------
  Weight (kg)                     --0.039      0.809           0.316     **0.039**
  BMI (kg/m^2^)                   0.009        0.955           0.198     0.203
  Arm circumference (cm)          --0.201      0.207           0.285     0.064
  Muscle arm circumference (cm)   --0.174      0.276           0.396     **0.009**
  Waist perimeter (cm)            0.113        0.506           0.040     0.806
  Abdominal circumference (cm)    0.033        0.878           0.255     0.191
  Calf circumference (cm)         0.094        0.621           0.180     0.316
  Basal metabolism (kcal)         --0.019      0.909           0.365     **0.016**
  Fat mass (kg)                   --0.070      0.622           0.144     0.357
  %Fat mass                       --0.128      0.430           0.053     0.741
  Fat free mass (kg)              0.044        0.785           0.358     **0.018**
  \% Fat free mass                0.194        0.224           --0.028   0.858
  Total water (kg)                0.042        0.794           0.364     **0.017**
  %Total water                    0.154        0.336           --0.077   0.623
  Speed at 2.44 m (seconds)       --0.018      0.912           0.258     0.095
  Speed at 4.55 m (seconds)       0.165        0.310           --0.086   0.588
  Speed at 3 m (seconds)          --0.144      0.370           0.106     0.498
  Grip strength (kg)              0.264        0.096           --0.048   0.761
  Glucose (mg/dl)                 --0.036      0.829           --0.071   0.665
  Insulina (μIU/ml)               --0.164      0.339           --0.192   0.218
  HbA1c (%)                       0.146        0.368           --0.181   0.249
  HOMA                            --0.070      0.698           --0.163   0.316
  Albumin (g/dl)                  0.153        0.358           0.023     0.890
  Protein (g/dl)                  --0.102      0.535           --0.197   0.212
  Total cholesterol (mg/dl)       --0.044      0.784           --0.107   0.494
  HDL cholesterol (mg/dl)         --0.058      0.718           0.008     0.958
  LDL cholesterol mg/dl)          --0.107      0.513           --0.008   0.580
  Tryglicerides (mg/dl)           0.144        0.369           --0.086   0.582
  C-reactive protein (mg/dl)      0.249        0.126           --0.388   **0.012**
  Leucocytes                      --0.187      0.254           --0.039   0.808
  Neutrophils                     0.079        0.635           --0.066   0.681
  Lymphocytes                     --0.159      0.335           --0.200   0.209

Bold values mean statistical significance (

p

\< 0.05).

![Bivariate correlation between circulating myostatin and speed at 2.44 m at baseline in control group.](fphys-10-00871-g002){#F2}

At follow up, no significant associations among irisin, anthropometrical and clinical parameters in control ([Table 6](#T6){ref-type="table"}), RE ([Table 7](#T7){ref-type="table"}) or RENS ([Table 8](#T8){ref-type="table"}) were found. In control group, circulating myostatin was positively correlated BMI, abdominal circumference, total water, HOMA, triglycerides, C-reactive protein ([Table 6](#T6){ref-type="table"}), but these associations were not observed in RE ([Table 7](#T7){ref-type="table"}) or RENS groups ([Table 8](#T8){ref-type="table"}).

###### 

Bivariate correlations between anthropometrical and clinical parameters and circulating irisin and myostatin in control group at follow-up.

                                  **Irisin**   **Myostatin**             
  ------------------------------- ------------ --------------- --------- -----------
  Weight (kg)                     --0.021      0.940           0.370     0.109
  BMI (kg/m^2^)                   0.002        0.995           0.464     **0.039**
  Arm circumference (cm)          --0.013      0.964           0.196     0.422
  Muscle arm circumference (cm)   0.143        0.626           0.345     0.148
  Waist perimeter (cm)            --0.040      0.893           0.423     0.071
  Abdominal circumference (cm)    0.014        0.966           0.487     **0.041**
  Calf circumference (cm)         0.353        0.215           --0.107   0.662
  Basal metabolism (kcal)         0.011        0.970           0.388     0.091
  Fat mass (kg)                   --0.103      0.725           0.366     0.123
  %Fat mass                       --0.263      0.344           0.065     0.784
  Fat free mass (kg)              --0.046      0.876           0.337     0.158
  \% Fat free mass                0.169        0.563           --0.131   0.593
  Total water (kg)                0.058        0.851           0.547     **0.019**
  %Total water                    0.236        0.437           --0.024   0.925
  Speed at 2.44 m (seconds)       --0.109      0.699           0.387     0.092
  Speed at 4.55 m (seconds)       0.091        0.747           0.239     0.310
  Speed at 3 m (seconds)          --0.247      0.375           0.268     0.253
  Grip strength (kg)              0.071        0.800           --0.078   0.743
  Glucose (mg/dl)                 --0.446      0.110           0.297     0.217
  Insulina (μIU/ml)               --0.258      0.394           0.308     0.187
  HbA1c (%)                       --0.201      0.472           0.051     0.829
  HOMA                            --0.371      0.236           0.508     **0.026**
  Albumin (g/dl)                  --0.013      0.964           --0.130   0.585
  Protein (g/dl)                  --0.069      0.816           0.131     0.594
  Total cholesterol (mg/dl)       --0.339      0.216           --0.333   0.151
  HDL cholesterol (mg/dl)         --0.232      0.405           --0.348   0.133
  LDL cholesterol mg/dl)          --0.338      0.218           --0.348   0.133
  Tryglicerides (mg/dl)           0.289        0.297           0.462     **0.040**
  C-reactive protein (mg/dl)      --0.068      0.810           0.528     **0.017**
  Leucocytes                      --0.147      0.615           0.120     0.624
  Neutrophils                     --0.101      0.730           0.227     0.349
  Lymphocytes                     0.056        0.844           --0.320   0.169

Bolded values mean statistical significance (

p

\< 0.05).

###### 

Bivariate correlations between anthropometrical and clinical parameters and circulating irisin and myostatin in resistance exercise group at follow-up.

                                  **Irisin**   **Myostatin**             
  ------------------------------- ------------ --------------- --------- -----------
  Weight (kg)                     0.059        0.835           --0.147   0.615
  BMI (kg/m^2^)                   --0.157      0.576           0.055     0.852
  Arm circumference (cm)          0.122        0.664           --0.283   0.327
  Muscle arm circumference (cm)   0.018        0.950           --0.218   0.455
  Waist perimeter (cm)            0.030        0.914           --0.081   0.782
  Abdominal circumference (cm)    0.500        0.667           --0.500   0.667
  Calf circumference (cm)         --0.109      0.711           --0.320   0.287
  Basal metabolism (kcal)         0.113        0.689           --0.385   0.175
  Fat mass (kg)                   --0.027      0.937           0.115     0.751
  %Fat mass                       --0.122      0.666           0.415     0.140
  Fat free mass (kg)              0.172        0.594           --0.391   0.235
  \% Fat free mass                0.193        0.490           --0.431   0.124
  Total water (kg)                0.077        0.821           --0.745   **0.013**
  %Total water                    0.296        0.377           --0.091   0.803
  Speed at 2.44 m (seconds)       0.161        0.566           --0.167   0.568
  Speed at 4.55 m (seconds)       0.165        0.558           --0.123   0.675
  Speed at 3 m (seconds)          --0.113      0.689           --0.279   0.334
  Grip strength (kg)              0.227        0.416           --0.266   0.358
  Glucose (mg/dl)                 0.065        0.819           --0.651   **0.012**
  Insulina (μIU/ml)               --0.134      0.647           0.385     0.175
  HbA1c (%)                       0.174        0.534           --0.527   0.053
  HOMA                            --0.147      0.615           0.345     0.227
  Albumin (g/dl)                  0.045        0.874           --0.070   0.812
  Protein (g/dl)                  --0.274      0.322           0.372     0.191
  Total cholesterol (mg/dl)       --0.441      0.099           0.402     0.154
  HDL cholesterol (mg/dl)         --0.213      0.446           0.284     0.325
  LDL cholesterol mg/dl)          --0.396      0.161           0.560     **0.046**
  Tryglicerides (mg/dl)           --0.133      0.636           --0.009   0.976
  C-reactive protein (mg/dl)      --0.184      0.529           0.033     0.915
  Leucocytes                      --0.214      0.443           0.051     0.864
  Neutrophils                     0.014        0.960           0.221     0.449
  Lymphocytes                     --0.432      0.108           --0.150   0.609

Bold values mean statistical significance (

p

\< 0.05).

###### 

Bivariate correlations between anthropometrical and clinical parameters and circulating irisin and myostatin in resistance exercise and nutritional support group at follow-up.

                                  **Irisin**   **Myostatin**             
  ------------------------------- ------------ --------------- --------- -----------
  Weight (kg)                     --0.233      0.546           0.517     0.154
  BMI (kg/m^2^)                   --0.267      0.488           0.150     0.700
  Arm circumference (cm)          --0.400      0.286           0.033     0.932
  Muscle arm circumference (cm)   --0.517      0.154           0.717     **0.030**
  Waist perimeter (cm)            0.133        0.732           0.467     0.205
  Abdominal circumference (cm)    --0.143      0.736           0.238     0.570
  Calf circumference (cm)         0.554        0.154           --0.289   0.487
  Basal metabolism (kcal)         0.183        0.637           0.350     0.356
  Fat mass (kg)                   --0.250      0.516           0.133     0.732
  %Fat mass                       --0.350      0.356           --0.150   0.700
  Fat free mass (kg)              0.183        0.637           0.350     0.356
  \% Fat free mass                0.350        0.356           0.150     0.700
  Total water (kg)                0.083        0.831           --0.117   0.765
  %Total water                    0.343        0.366           0.142     0.715
  Speed at 2.44 m (seconds)       --0.550      0.125           0.267     0.488
  Speed at 4.55 m (seconds)       --0.483      0.187           0.300     0.433
  Speed at 3 m (seconds)          --0.583      0.099           0.183     0.637
  Grip strength (kg)              0.467        0.205           0.250     0.516
  Glucose (mg/dl)                 0.633        0.067           --0.133   0.732
  Insulina (μIU/ml)               0.450        0.224           --0.150   0.700
  HbA1c (%)                       0.611        0.081           --0.569   0.110
  HOMA                            0.450        0.224           --0.150   0.700
  Albumin (g/dl)                  0.061        0.877           0.087     0.325
  Protein (g/dl)                  --0.042      0.915           0.244     0.527
  Total cholesterol (mg/dl)       0.276        0.472           --0.377   0.318
  HDL cholesterol (mg/dl)         --0.159      0.683           --0.460   0.213
  LDL cholesterol mg/dl)          0.200        0.606           --0.150   0.700
  Tryglicerides (mg/dl)           0.483        0.187           --0.233   0.546
  C-reactive protein (mg/dl)      0.310        0.417           --0.870   **0.002**
  Leucocytes                      0.500        0.207           --0.381   0.352
  Neutrophils                     0.790        **0.020**       --0.323   0.435
  Lymphocytes                     --0.211      0.586           --0.270   0.482

Bold values mean statistical significance (

p

\< 0.05).

The walking speed decreased significantly in C and RE group, moving from 3.75 to 3.4 m/s at the end (*p* = 0.016) in C and from 3.9 m/s to a at follow-up speed of 3.2 m/s (*p* = 0.003) in RE, but not in RENS, in which walking speed change from 3.9 m/s to a at follow-up speed of 3.8 m/s (*p* = 0.791) ([Table 2](#T2){ref-type="table"}).

Discussion {#S4}
==========

In this clinical trial, the impact of low-intensity resistance exercise and nutritional assistance program on body composition, anthropometric parameters, strength, speed of motion and myokines were examined in elderly people.

Body Composition and Anthropometric Parameters {#S4.SS1}
----------------------------------------------

Current data confirmed that low intensity exercising program and nutritional assistance prevented muscle deterioration in people aged 60--75 years old. Exercise improves muscle mass and contributes to the maintenance of daily life activities ([@B37]). Both aerobic and resistance exercise delay the deterioration of the muscles, but resistance exercise seems the most effective ([@B58]). Here, we showed that 16-week low intensity resistance program produced significant changes on body composition (fat mass, percent fat mass, fat-free mass, muscle mass kg and the calf circumference). These results were expected and are in agreement with previous studies ([@B35]), and indicated that low intensity resistance training promotes musculature improvement, is a useful and simple therapeutic approach to prevent sarcopenia, and when was combined with protein supplementation these beneficial effects were enhanced ([@B35]). However, resistance training presents some limitations ([@B43]; [@B39]; [@B66]). For instance, one important limitation was the rapid loss of beneficial effects, such as the gain of muscle mass (in the study the improvement is 0.7% *p* \< 0.001) and adherence to exercise. The study's approach of performing low-intensity resistance exercises aims to inform to the subject about exercise strategies that can be performed at home, since equipment is not required to be able to perform them, and the importance of training as long as possible without causing muscle overload injuries ([@B24]).

In control group, waist and calf circumference were reduced in parallel to fat free mass and decreased speed at 3 m, indicating aging-associated body weight reduction ([@B15]), muscle mass loss and worsening of physical condition. Elderly associated physical inactivity is known to accelerate muscle mass loss ([@B16]). In fact, physical activity reduced the progression of muscle aging and decreased the strength of muscle contraction ([@B21]; [@B67]), attenuating sarcopenia in pre- and post-menopausal women ([@B60]) and in older men ([@B51]). On the other hand, 10 days of bed rest resulted in a significant decreased lean mass and skeletal muscle loss in healthy older adults, even greater than young individuals after 28 days ([@B27]).

Otherwise, the reduction of HbA1c from 5.8 to 5.7 has not clinical relevance.

Here, we found the following effects of resistance training on strength, speed and myokines:

1.  *Strength.* Resistance training is the most effective strategy to increase muscle mass and strength ([@B33]; [@B65]). Being the grip strength is a good indicator of low muscle mass ([@B29]), this parameter detects individuals with low muscle mass that will make them more fragile and with greater risk of disability ([@B36]; [@B52]). We observed that there was no significant association between the concentration of myostatin and muscular force, as concluded by [@B9].

2.  *Speed.* It is known that exercise interventions that increase muscle strength are very effective in improving walking speed ([@B18]). In the present study, the walking speed decreased in all groups producing in improvement of 15% in control group, 14% in Resistance Exercise group, and 7% in Resistance Exercise and Nutritional Support group. Different studies have shown improvements between 3 and 10% ([@B41]), being the results obtained in the current study similar to those reported. The walking speed reflects the health and functionality of the person ([@B1]). This is recommended as a clinical indicator to assess survival. In a meta-analysis published in 2011 in the journal JAMA by [@B50] walking speed within their range of normality behaves as a protective factor against mortality, being the lowest in those individuals with faster walking. A lower driving speed is usually associated with disability, cognitive deterioration, accidental falls, various neurological diseases, cardiopulmonary and orthopedic diseases that contribute to increase mortality rate ([@B1]; [@B50]).

3.  *Myokines.* Myostatin is a hormone that is mainly expressed in the muscle and inhibits the formation of muscle mass. Myostatin is generated as a precursor protein that requires the proteolytic division to release the N-terminal and the C-terminal propeptide. The active form of myostatin is a disulfide dimer attached to the C-terminal fragment ([@B61]).

    Myostatin increases with age, although differences in total vs. active form have not been well investigated ([@B64]). The current study, that analyzed serum myostatin concentrations before and after the resistance exercise program, found results that are contradictory with those reported in the literature. In the control group, circulating myostatin concentration decreased significantly after 16 weeks, in parallel to decreased fat free mass, whereas, in RE and RENS group, myostatin remained unchanged after the exercise, and fat free mass increased. These findings were in hard contrast to previous studies that demonstrated negative effects of myostatin in muscle mass development ([@B40]; [@B32]; [@B68]; [@B62]; [@B31]). Possibly, in control group, a reduction of myostatin causes significant decrease in primary fibers of skeletal muscle, which is associated with increased fatigue susceptibility ([@B19]), indicating physical condition decline. In line with current data, in a recent study low serum myostatin levels have been associated with low skeletal muscle ([@B47]). Muscular force exercise is known to inhibit local myostatin ([@B6]). However, [@B28] observed increased secretion of myostatin in blood in response to exercise. As, the antibodies used to detect myostatin (current ELISA) did not distinguish between the active or latent form, further research is needed.

    Irisin is a myokine produced by the proteolytic cleavage of the membrane-protein, fibronectin type III "domain-containing" protein-5 (FNDC5) ([@B5]). It is regulated by peroxisome proliferator activated receptor (PPAR) and peroxisome proliferator activated receptor γ co-activator-1-α (PGC1α). It is suggested that irisin may act in some of the beneficial effects of exercise by inducing the uncoupling protein one (UCP-1), that afterward increases the energy expenditure of white adipocytes, process called "browning." This process is characterized by a switch of white to beige adipose tissue in response to β-adrenergic stimuli (exposure to cold and physical activity) ([@B45]). In humans, the effect of exercise on irisin production has provided contradictory findings ([@B22]; [@B30]; [@B54]). [@B22] correlated the decrease in the circulating irisin concentration with the loss of muscle mass associated to aging. A recent study by [@B10] concluded that a low blood concentration of irisin was a sensitive molecular marker for muscle weakness and atrophy. In post-menopausal women, decreased serum irisin concentration is an independent predictor of sarcopenia ([@B46]). In fact, irisin has been proposed as a molecule that combines beneficial effects for treating osteoporosis and muscular atrophy through its effects restoring bone and preventing muscle wasting ([@B26]; [@B12]).

    In agreement with these studies, current findings indicated that RE and RENS resulted in increased circulating irisin in parallel to strength and walking speed in elderly subjects. In fact, decreased circulating irisin was significantly associated with strength loss at the end of the study ([Figure 1B](#F1){ref-type="fig"}). Thus, irisin could be a potential biomarker of muscle dysfunction ([@B10]).

In relation to protein supplementation, several studies indicated that protein supplementation improved the adaptations of resistance exercise ([@B7]; [@B8]; [@B14]; [@B23]; [@B59]; [@B44]). [@B14] reported a 5 kg increase of fat-free mass after 10 weeks of resistance training combined with 45 g/day ingest of milk protein. [@B7], [@B8] demonstrated that milk protein supplementation during 6 weeks of resistance training promoted an increase of 2.3--2.5 kg of fat-free mass. [@B23] also reported that supplementation with milk protein and 10 weeks of resistance exercise resulted in an increase of 2.5 kg fat free mass. [@B59] reported that supplementation with milk protein from cow or soy in addition with resistance training for 9 months increased by 3.6 and 2.6 kg of fat-free mass, respectively. [@B44] suggest that one of the mechanisms responsible for the enhancement of skeletal mass could be explained for the improvement of the anabolism of skeletal muscle. These positive effects of protein supplementation do not have the same effects as isolated supplementation with amino acids ([@B4]; [@B56]; [@B2]). In line with all these studies, current findings confirmed an improvement in fat-free mass in the exercise group with cow milk protein supplementation. Even though, this improvement was not so marked as that described in the literature, probably due to relative low protein supplementation (10 g of protein every day and 20 g during exercise days) did not reach the threshold to promote anabolism of muscle protein in older people ([@B55]). An important consideration is that the attachment to nutritional support was not homogeneous in all participants.

Resistance exercise and nutritional support resulted in improved anthropometric parameters (muscle arm circumference, calf circumference, basal metabolism and fat free mass) compared with RE intervention. The improvement in walking speed and grip strength was not so marked in the RENS group compared to RE intervention. These differences could be due to significant increased mean age in RENS compared to RE subjects.

Conclusion {#S5}
==========

A program of physical exercise of low intensity resistance, together with a nutritional support, improved the deterioration of the musculature in people aged 60--75. Circulating irisin, but not myostatin, constituted a marker for improved muscle strength after resistance exercise in elderly subjects.
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